Claudiximab

Drug Profile

Claudiximab

Alternative Names: iMAB 362

Latest Information Update: 26 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ganymed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Claudin 18 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer
  • Phase I Pancreatic cancer
  • Preclinical Solid tumours

Most Recent Events

  • 26 Dec 2016 Preclinical trials in Solid tumours in Germany (IV)
  • 21 Dec 2016 Ganymed Pharmaceuticals has been acquired by Astellas Pharma
  • 07 Oct 2016 Efficacy data from a phase II trial in Gastric cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top